{"id":"lu-aa24530","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Headache"},{"rate":"6%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2104986","moleculeType":"Small molecule","molecularWeight":"283.44"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lu AA24530 is a selective 5-HT6 receptor antagonist, which is believed to exert its therapeutic effects by modulating the activity of the 5-HT6 receptor in the brain.","oneSentence":"Selective 5-HT6 receptor antagonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:38:43.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of schizophrenia"}]},"trialDetails":[{"nctId":"NCT00599911","phase":"PHASE2","title":"Dose-finding Study With Lu AA24530 in Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-10","conditions":"Major Depressive Disorder","enrollment":652}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Lu AA24530","genericName":"Lu AA24530","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selective 5-HT6 receptor antagonist Used for Treatment of schizophrenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}